Biogen And Eisai's LEQEMBI Intravenous Infusion Secures Approval In Japan For The Treatment Of Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Biogen (BIIB) and Eisai's (ESAIY) LEQEMBI intravenous infusion has received approval in Japan for the treatment of Alzheimer's disease.
September 25, 2023 | 5:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's Alzheimer's treatment, LEQEMBI, co-developed with Eisai, has been approved in Japan.
The approval of LEQEMBI in Japan is a significant milestone for Biogen. This could potentially increase the company's revenue and improve its market position in the Alzheimer's treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Eisai's Alzheimer's treatment, LEQEMBI, co-developed with Biogen, has been approved in Japan.
The approval of LEQEMBI in Japan is a significant milestone for Eisai. This could potentially increase the company's revenue and improve its market position in the Alzheimer's treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100